# Ramaswamy Govindan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ramaswamy-govindan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 109,570 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 130 |
| i10-index | 402 |
| Last Known Institution | University of Washington |
| OpenAlex ID | https://openalex.org/A5068824818 |
| ORCID iD | https://orcid.org/0000-0002-6964-9612 |
| Works | 1,268 |

## Researcher papers

- [Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database](https://scholariq.org/papers/changing-epidemiology-of-small-cell-lung-cancer-in-the-united-states-over-the/)
- [Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation](https://scholariq.org/papers/sotorasib-for-lung-cancers-with-i-kras-i-p-g12c-mutation/)
- [KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors](https://scholariq.org/papers/kras-sup-g12c-sup-inhibition-with-sotorasib-in-advanced-solid-tumors/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-1-2020/)
- [NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016](https://scholariq.org/papers/nccn-guidelines-insights-non-small-cell-lung-cancer-version-4-2016/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study](https://scholariq.org/papers/alectinib-in-crizotinib-refractory-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study](https://scholariq.org/papers/rovalpituzumab-tesirine-a-dll3-targeted-antibody-drug-conjugate-in-recurrent/)
- [Non–Small Cell Lung Cancer, Version 6.2015](https://scholariq.org/papers/non-small-cell-lung-cancer-version-6-2015/)
- [Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-trial-of-ipilimumab-combined-with-paclitaxel-and-carboplatin-in/)
- [Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pooled-analysis-of-cns-response-to-alectinib-in-two-studies-of-pretreated/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [University of Washington](https://scholariq.org/institutions/university-of-washington/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.